Pfizer, Valneva remove half of participants from study of Lyme disease shot
Merck seeks more approvals for infectious disease drug
Sanofi and Regeneron face a high-risk test for Dupixent
GSK expresses no regrets on abandoning cell therapy as oligo strategy heats up
*please scroll down for all the latest news*
